August 9, 2021 10:51 AM EDT
Deals
Pharma

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

Max Gelman

Senior Editor

One of the pro­grams that head­lined Ab­b­Vie’s $63 bil­lion ac­qui­si­tion of Al­ler­gan is be­ing re­turned to its de­vel­op­ers af­ter an FDA re­jec­tion last year. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times